ArticleAJOG global reports2025
Increased prevalence of parvovirus B19 infection among pregnant women in central Italy and genomic analysis.
Article in AJOG global reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Parvoviruses at the Heart: Endothelial Injury and Myocyte Lysis in Human B19V and Canine CPV-2 Infections.Current issues in molecular biology · 2025Review
- Temporal, Spatial and Seasonal Patterns of Parvovirus B19 Seroepidemiology in Childbearing-Aged Women in Croatia, 2015-2024.Viruses · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDuring 2024, the number of pregnant women who tested positive for parvovirus B19 in central Italy significantly increased. Genome sequence analysis of parvovirus B19 detected in blood samples of pregnant women revealed the co-circulation of 2 distinct clusters belonging to genotype 1, with nucleotide differences in both nonstructural and VP1 and VP2 proteins. The European Centre for Disease Prevention and Control declares a considerable increase in parvovirus B19 infections among children, pregnant women, and blood donors across most European nations from late 2023.
objectiveThis study aimed to evaluate the positivity rate of parvovirus B19 infections among Italian pregnant women attending the maternal-fetal infection prevention outpatient care facility at the National Institute for Infectious Diseases Lazzaro Spallanzani of Rome for routine evaluation of maternal-fetal infections. STUDY
designBlood samples from 139 pregnant women were analyzed for parvovirus B19 infection according to the physician's request: parvovirus B19 immunoglobulin M and immunoglobulin G antibodies and/or parvovirus B19 DNA. Among these samples, 8 positive for parvovirus B19 DNA were subjected to target amplicon sequencing and whole-genome reconstruction. For phylogenetic analysis, all parvovirus B19 complete genome sequences were collected, and multisequence alignment was performed to develop the best tree model.
resultsA sharp increase in parvovirus B19 circulation among Italian pregnant women occurred, starting from the end of 2023. During the first 9 months of 2024, requests for diagnosis of parvovirus B19 infection continued to increase significantly, and 46% of the samples analyzed in the first 9 months of the year were positive for parvovirus B19 infection. Phylogenetic analysis showed that all viruses detected belonged to parvovirus B19 genotype 1 and were clustered in 2 separate phylogenetic groups: one similar to the PP818758 genome sequence from France in 2024 and one similar to the KM393165 genome sequence from the United States in 2013. In addition, whole-genome sequence alignment revealed nucleotide mutations that caused amino acid changes, distinguishing the National Institute for Infectious Diseases clusters from similar sequences: the F8L, R54K, and F517S substitutions in the nonstructural gene of the viral genome for cluster 1 and the C298S, E195D, and T456S mutations in the nonstructural, VP1, and VP1 + VP2 genes for cluster 2. Furthermore, the C298S mutation was observed for the first time, as this mutation has never been detected in any other parvovirus B19 genome sequences submitted to international databases.
conclusionSince the beginning of 2024, Italy, similar to many European countries, has been experiencing an epidemic of parvovirus B19 infection among pregnant women, with a positivity rate increasing to 46% in the first 9 months of the year. The peak incidence observed in this period seems to be significantly higher than that observed in the same period of the years 2021-2023. Because parvovirus B19 infection can cause up to 20% of asymptomatic infections with serious consequences for the fetus, it is essential to enhance screening and surveillance to stop virus transmission and dissemination, particularly during epidemic periods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.